We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

25 hedge funds and large institutions have $4.35M invested in F-star Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more capital invested

Capital invested by funds: $2.77M → $4.35M (+$1.58M)

11% less funds holding

Funds holding: 28 → 25 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

70% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 10

Holders
25
Holders Change
-3
Holders Change %
-10.71%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
10
Closed
5
Calls
$294K
Puts
–
Net Calls
+$294K
Net Calls Change
+$108K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$196K
2
ECM
ExodusPoint Capital Management
New York
+$23.1K
3
TRCT
Tower Research Capital (TRC)
New York
+$11.3K
4
Northern Trust
Northern Trust
Illinois
+$6.88K
5
Wells Fargo
Wells Fargo
California
+$6

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$68.3K
2
BlackRock
BlackRock
New York
-$48.4K
3
PCM
Parsons Capital Management
Rhode Island
-$33.7K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$24K
5
BI
BVF Inc
California
-$15.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$1.38M -$15.2K -2,632 -1%
Renaissance Technologies
2
Renaissance Technologies
New York
$695K +$196K +33,901 +40%
Vanguard Group
3
Vanguard Group
Pennsylvania
$649K -$10.4K -1,807 -2%
TA
4
Tiedemann Advisors
New York
$533K – – –
BlackRock
5
BlackRock
New York
$270K -$48.4K -8,371 -15%
ED
6
Exane Derivatives
France
$120K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$113K – – –
PCM
8
Parsons Capital Management
Rhode Island
$88K -$33.7K -5,834 -28%
PCA
9
Private Capital Advisors
Connecticut
$77K – – –
SAM
10
Silvercrest Asset Management
New York
$75K – – –
Bank of New York Mellon
11
Bank of New York Mellon
New York
$66K – – –
Northern Trust
12
Northern Trust
Illinois
$65K +$6.88K +1,190 +12%
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$49K -$798 -138 -2%
Morgan Stanley
14
Morgan Stanley
New York
$30K -$110 -19 -0.4%
LF
15
Lee Financial
Texas
$28K – – –
PAM
16
Pegasus Asset Management
New York
$28K – – –
ECM
17
ExodusPoint Capital Management
New York
$23K +$23.1K +3,988 New
CAG
18
Crestwood Advisors Group
Massachusetts
$19K -$3.61K -625 -16%
AIM
19
Arcadia Investment Management
Michigan
$18K – – –
TRCT
20
Tower Research Capital (TRC)
New York
$11K +$11.3K +1,959 New
GT
21
Glenmede Trust
Pennsylvania
$6K – – –
JP Morgan Chase
22
JP Morgan Chase
New York
$3K -$68.3K -11,815 -95%
UBS Group
23
UBS Group
Switzerland
$1K -$6.21K -1,073 -90%
BNP Paribas Financial Markets
24
BNP Paribas Financial Markets
France
$3 -$104 -18 -95%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
– -$24K -6,553 Closed
1
2

FSTX Hedge Fund Activity: Q2 2020 in Review

25 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2020, worth a combined $4.35M — up 57% from $2.77M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of FSTX and 2 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $196K. The largest seller was JP Morgan Chase, cutting an estimated $68.3K.

  • 25 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2020, down from 28 in Q1 2020.
  • Funds reported $4.35M of F-star Therapeutics, Inc. Common Stock stock for Q2 2020, up 57% quarter-over-quarter.
  • 2 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2020 and 5 closed out, a net change of -3 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2020 was Renaissance Technologies, an estimated $196K added.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q2 2020 was JP Morgan Chase, an estimated $68.3K sold.

Based on aggregated 13F filings for Q2 2020.